Applied DNA Sciences, Inc.
5.62+1.35 (+31.6%)
Oct 6, 4:00:01 PM EDT · NasdaqCM · APDN · USD
Key Stats
Market Cap
7.26MP/E (TTM)
-Basic EPS (TTM)
-57.12Dividend Yield
0%Recent Filings
8-K
Restructuring for BNB strategy
Applied DNA Sciences launched a restructuring on September 30, 2025, slashing its workforce by 60%—16 employees—to channel resources into its BNB-focused treasury strategy. This move triggers $1.4 million in pre-tax charges, mostly severance, but promises $2.9 million in annual savings, with completion by October's end. Ticker switches to BNBX on October 7, signaling the pivot. Yet volatility in digital assets looms large.
8-K
Applied DNA's crypto pivot
Applied DNA Sciences announced a $26.8 million private placement of common stock, prefunded warrants, and common warrants closing around October 1, 2025, accepting cash or cryptocurrency, to fund a BNB-focused treasury strategy involving staking and yield opportunities. Amid this pivot from biotechnology, CEO Judith Murrah resigned effective September 29, 2025, with Clay Shorrock stepping in as CEO. Leadership shakeup signals bold crypto bet, yet execution risks loom in volatile markets.
8-K
Q3 revenues down, restructuring advances
Applied DNA Sciences reported Q3 fiscal 2025 results on August 14, 2025, with revenues dropping to $304 thousand from $473 thousand a year ago, amid a $3.7 million operating loss. The company sharpened its focus on LineaRx's cell-free DNA and mRNA platforms after closing its MDx Testing Services and winding down DNA Tagging segments, securing a $600 thousand LineaDNA order from an IVD manufacturer. Cash burn fell 19% sequentially to $934 thousand monthly. Restructuring positions it for growth, yet ongoing losses persist.
10-Q
Q3 FY2025 results
Applied DNA Sciences posted Q3 FY2025 revenue of $304K, down 36% y/y from $473K amid the wind-down of its tagging business, yet YTD revenue climbed 19% y/y to $1.9M, fueled by 31% y/y growth in Therapeutic DNA Production Services product sales to $1.2M. Gross margin eroded to 2% from 51% y/y, reflecting lower volumes absorbing fixed costs, while operating loss widened 12% y/y to $3.7M on higher SG&A from executive separation costs. Cash burned $9.1M in operating activities YTD, leaving $4.7M at quarter-end after $7.9M in equity raises; free cash flow not disclosed in the 10-Q. The firm slashed headcount 39% since January for 31% payroll cuts, exiting diagnostics via discontinued operations with $336K Q3 loss. Warrant modifications triggered $15.5M deemed dividend, diluting EPS to $(34.00) basic/diluted (anti-dilution flagged). Nasdaq bid price compliance remains precarious.
8-K
Regains Nasdaq compliance
Applied DNA Sciences regained Nasdaq compliance on July 2, 2025, after meeting the $1.00 minimum bid price rule under Listing Rule 5550(a)(2). This cancels the scheduled July 15 hearing and ensures continued listing and trading. Compliance stabilizes the stock's market access. No further risks disclosed.
A
Agilent Technologies, Inc.
143.20-2.65
CDNA
CareDx, Inc.
14.28-0.39
DGX
Quest Diagnostics Incorporated
174.78-3.50
DHR
Danaher Corporation
214.01-2.89
IDXG
Interpace Biosciences, Inc.
1.10-0.04
ILMN
Illumina, Inc.
95.03-2.77
NNNN
Anbio Biotechnology
21.65-1.69
QGEN
Qiagen N.V.
47.19-0.76
TWST
Twist Bioscience Corporation
32.21-1.36
WGS
GeneDx Holdings Corp.
131.76-5.71